Head-to-head evidence
Gefitinib vs JS111 AP-L1898
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Gefitinib
Marketed by AstraZeneca
NCT00020709 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial with 840 participants and hard clinical primary endpoints of overall survival and progression-free survival. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT03333343 (registry estimate)
JS111 AP-L1898
Developed by Shanghai Junshi Bioscience
NCT04993391 · Phase 1/2 · status unknown
This is a single-arm, open-label, non-randomized dose-escalation study in 156 people with advanced non-small cell lung cancer, testing five ascending doses with no control group. It is designed primarily to characterize safety, with response rate as a secondary readout, and no results have been posted.
Next expected readout: July 2028 · NCT06940401 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gefitinib's landscape · JS111 AP-L1898's landscape